How would you manage a patient who developed stage III melanoma while receiving cemiplimab (cycle 10) for locally advanced cutaneous squamous cell carcinoma?

If a BRAF mutation is identified, would you consider adjuvant BRAF/MEK inhibitors, or would you opt for high-dose ipilimumab at 10 mg/kg? Are there any other treatment strategies you would consider?"

Answer from: Medical Oncologist at Academic Institution

Is this clinical stage 3 or stage 3 melanoma with microscopic metastasis to the lymph node? If clinical stage 3 melanoma, then perhaps, I think the best route to go would be to treat with ipi-nivo combination. I would prefer to use ipi-3 and nivo-1 based on the S1616 data rather than ipi-1 and nivo-...

Please select the option that best describes you:

How would you manage a patient who developed stage III melanoma while receiving cemiplimab (cycle 10) for locally advanced cutaneous squamous cell carcinoma?

Related Questions